Vancomycin Therapeutic Drug Monitoring (TDM) and Its Association with Clinical Outcomes: A Retrospective Cohort

Al-Maqbali, Juhaina Salim; Shukri, Zahra Al; Sabahi, Nawf Al; Al-Riyami, Intisar; Alawi, Abdullah M Al

doi:10.1016/j.jiph.2022.04.007

Cited by 16 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were only 14.5% patients whose TDM met the optimal target range of 15 to 20 mg/L in our study. Al-Maqbali et al showed that the vancomycin therapeutic level was not achieved in 16.8% of patients, and 47.5% of them had high vancomycin levels (>20 mg/L), 8 which was consistent with our study results. Subtherapeutic concentrations were measured by Van Der Heggen in 68% of adults in their study, showing that it is common for vancomycin TDM to not meet the optimal target.…”

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

“…7 Inappropriate therapeutic drug monitoring (TDM) time points and nonalternative daily doses may lead to a trough concentration that does not achieve the optimal target and contributes to adverse clinical outcomes. 8 Previous studies showed that the vancomycin trough concentration in CRRT patients has a wide variability. [9][10][11][12][13] The purpose of this study was to investigate vancomycin TDM in patients on CRRT and explore the risk factors of vancomycin trough concentrations that exceeded the target.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vancomycin therapeutic drug monitoring in patients on continuous renal replacement therapy: a retrospective study

et al. 2022

View full text Add to dashboard Cite

Objectives This study aimed to investigate vancomycin therapeutic drug monitoring (TDM) in patients on continuous renal replacement therapy (CRRT) and explore the risk factors for exceeding the target concentration. Methods This retrospective study enrolled patients aged ≥18 years who were admitted to the intensive care unit and treated with ≥3 intravenous vancomycin doses during CRRT, and who underwent vancomycin TDM. Demographic and other information were collected. Multivariate logistic regression was used assess the risk factors for exceeding the target concentration. Results Sixty-nine patients were included, and 40.6% patients underwent TDM. Additionally, 14.5% of patients reached the optimal concentration, and 87.5% of patients who exceeded the target received a daily dose adjustment. The cumulative dose of vancomycin and serum albumin were risk factors for exceeding the target concentration in patients on CRRT. Conclusions Patients on CRRT did not meet the optimal vancomycin management; <50% of the patients routinely received vancomycin TDM, and <15% achieved the optimal concentration. Fewer patients in the subtherapeutic group received a daily dose adjustment than those who exceeded the target concentration. Cumulative vancomycin and serum albumin doses before TDM were the risk factors for exceeding the target concentration in CRRT patients.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vancomycin therapeutic drug monitoring in patients on continuous renal replacement therapy: a retrospective study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[1][2][3] The rational use of VAN is highly important in clinical practice, but is challenging due to its toxicity and narrow therapeutic window. 4,5 High VAN concentrations can be adverse, causing the most serious side effects such as kidney injury, nephrotoxicity and ototoxicity. 4,7,8 However, when the drug level cannot reach the effective dosage, this can lead to treatment failure and drug resistance.…”

Section: Introductionmentioning

confidence: 99%

A simple and rapid strategy for monitoring vancomycin concentration in serum using a multicolor immunosensor based on the ratio of gold nanobipyramids and a product of cetyltrimethylammonium bromide-blue oxide of 3,3′,5,5′-tetramethylbenzidine interaction

Yang

Liu

et al. 2023

Anal. Methods

View full text Add to dashboard Cite

show abstract

“…administration, which allows healthcare professionals to evaluate the efficacy of the vancomycin dosing regimen and clearance of the drug by the individual patient. In case of infections caused by MRSA, it is recommended to maintain trough levels in the range (15 -20 mg/L) [4].…”

mentioning

confidence: 99%

Saving Recourses and Controlling Wastage: 24-Hour Supply vs. Late Mix of Intravenous Vancomycin

Sabyani¹,

Taha²,

Suwayeh³

et al. 2022

Act Scie Nutr

View full text Add to dashboard Cite

Vancomycin is a potent tricyclic glycopeptide antibiotic, used to treat bacterial infections caused by Gram-positive bacteria. It is renally excreted. Therefore, monitoring trough levels is highly important to ensure safety and efficacy. Vancomycin has good stability after preparation, which lasts for weeks, depending on temperature. Hence, pharmacy, in KAMC-MNGHA, used to provide each patient with all doses to cover 24 hours. Unfortunately, because doses and/or frequency are usually increased/decreased for the patients based on their renal function and drug levels, many doses are not given and wasted. That practice has been changed to prepare each dose of vancomycin 2 -3 hours before time of administration. As a result, number of wasted doses has decreased significantly.Consequently, hospital resources are saved and shortage of essential materials is prevented.

show abstract

Vancomycin Therapeutic Drug Monitoring (TDM) and Its Association with Clinical Outcomes: A Retrospective Cohort

Cited by 16 publications

References 26 publications

Vancomycin therapeutic drug monitoring in patients on continuous renal replacement therapy: a retrospective study

Vancomycin therapeutic drug monitoring in patients on continuous renal replacement therapy: a retrospective study

A simple and rapid strategy for monitoring vancomycin concentration in serum using a multicolor immunosensor based on the ratio of gold nanobipyramids and a product of cetyltrimethylammonium bromide-blue oxide of 3,3′,5,5′-tetramethylbenzidine interaction

Saving Recourses and Controlling Wastage: 24-Hour Supply vs. Late Mix of Intravenous Vancomycin

Contact Info

Product

Resources

About